Spots Global Cancer Trial Database for Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Official Title: Combined Phase I-Phase II Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma
Study ID: NCT03448978
Conditions
Study Description
Brief Summary: This Phase I/II study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Virgina Cancer Specialists, Fairfax, Virginia, United States
Contact Details
Name: Metin Kurtoglu, MD, PhD
Affiliation: Cartesian Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
